A month after starting its first Phase III trial, QuatRx Pharmaceuticals Co. filed for its initial public offering, hoping to raise $86.25 million. (BioWorld Today)

A month after starting its first Phase III trial, QuatRx Pharmaceuticals Co. filed for its initial public offering, hoping to raise $86.25 million. (BioWorld Today)

BioCryst Pharmaceuticals Inc. is expanding development and marketing for its lead product, Fodosine, through a potential $190 million oncology deal with Mundipharma International Holdings Ltd. (BioWorld Today)

BioCryst Pharmaceuticals Inc. is expanding development and marketing for its lead product, Fodosine, through a potential $190 million oncology deal with Mundipharma International Holdings Ltd. (BioWorld Today)

Shares of Nastech Pharmaceutical Co. Inc. jumped 18 percent Wednesday on news of a potential $577 million deal with Procter & Gamble Pharmaceuticals Inc. to develop Nastech's nasal spray for osteoporosis. (BioWorld Today)